TDF/FTC/LPV/r + Placebo
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cirrhosis
Conditions
Primary Biliary Cirrhosis
Trial Timeline
Jun 1, 2012 → Aug 1, 2015
NCT ID
NCT01614405About TDF/FTC/LPV/r + Placebo
TDF/FTC/LPV/r + Placebo is a pre-clinical stage product being developed by Gilead Sciences for Primary Biliary Cirrhosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01614405. Target conditions include Primary Biliary Cirrhosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01614405 | Pre-clinical | Terminated |
Competing Products
20 competing products in Primary Biliary Cirrhosis